In vitro experimental evidence indicated that the inhibition of aberrant angiogenesis elicited by local or systemic administration of Sema3F in vivo may be mediated by the NRP2-dependent inhibition of VEGF production and Akt-mTOR signaling in tumor cells [32]. The gene discussed is NRP2; the disease is neoplasm.